Congress Overview

Breast cancer continues to be the second most common cause of cancer death in women in the United States. Results from numerous clinical trials continue to expand diagnostic/prognostic tools, therapeutic options, and supportive care strategies. Healthcare professionals need to be educated on current and emerging scientific data to make evidence-based treatment decisions and to provide optimal care for patients with breast cancer.

The NCCN 2020 Congress Series™: Breast Cancer with Updates from the 2019 San Antonio Breast Cancer Symposium (SABCS) will provide expert insights on the current standard of care for patients with breast cancer and include the latest clinical research updates from the 2019 SABCS to assist clinicians in formulating breast cancer management strategies. 

Intended Audience

This educational program is designed to meet the educational needs of physicians, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with breast cancer.

Educational Objectives

Genetic/Familial Risk Assessment for Breast Cancer: Controversies and Evolving Principals

  • Describe the role of genetic counseling for individuals with a personal and/or family history of breast cancer.
  • Identify both the utility of and difficulties associated with multi-gene testing.
  • Discuss controversies associated with direct-to-consumer genetic testing services.

Adjuvant and Neoadjuvant Therapies for Early Stage Breast Cancer, Including SABCS Updates

  • Compare and contrast data on the clinical safety and efficacy of neoadjuvant regimens in early stage breast cancer.
  • Recognize key patient and clinical factors that influence selection of systemic adjuvant therapy.
  • Discuss clinical data of new and emerging supportive care interventions to improve quality of life of patients undergoing neoadjuvant/adjuvant chemotherapy.

Surgical Management of Breast Cancer, Including SABCS Updates

  • Develop evidence-based approaches for the surgical management of the axilla in patients with early stage breast cancer.
  • Identify patients who do not need to undergo axillary lymph node biopsy.
  • Discuss new and emerging data related to management of the axilla.

Is There a Role for Proton Therapy in the Treatment of Breast Cancer?

  • Discuss various radiation therapy modalities used in breast cancer.
  • Outline potential clinical applications of proton beam radiation in breast cancer.
  • Review available clinical data supporting ongoing research on the role of proton beam radiation therapy for breast cancer.

Principles of Breast Reconstruction after Surgery

  • Outline the various techniques used for breast reconstruction.
  • Review the timing of breast reconstruction including the advantages and disadvantages of immediate versus delayed breast reconstruction.
  • Counsel patients on appropriate breast reconstruction procedure based on clinical factors and patient preference.

Biomarker Assays for Treatment Selection of Advanced Breast Cancer 

  • List available predictive biomarkers to guide therapeutic decisions in patients with advanced breast cancer.
  • Outline the currently used molecular profiling techniques.
  • Evaluate the available data to determine appropriate molecular assays for specific biomarkers.

Management of Metastatic Breast Cancer, Including SABCS Updates

  • Select evidence-based first- and subsequent-line treatment options for patients with metastatic breast cancer based on hormone- and HER2-receptor status.
  • List the current therapeutic approaches for triple negative metastatic breast cancer.
  • Outline new and emerging therapeutic options for patients with metastatic breast cancer.

Management of Toxicities with Targeted Therapies for Breast Cancer

  • Review the mechanism of action currently available targeted therapies.
  • Review safety profiles of targeted agents used in metastatic breast cancer.
  • Optimally manage drug interactions and common toxicities related to targeted agents.
  • Discuss and debate the rationale for adjuvant radiation therapy to treat patients with DCIS.
  • Assess the risk of recurrence and select optimal treatment strategies for patients with DCIS.

Management of Rare Breast Cancers

  • Outline the classification of histological subtypes of breast cancers.
  • Summarize the current knowledge of clinical and genomic aspects of rare breast cancer histologies.
  • Discuss emerging therapeutic strategies in management of select rare breast cancers.

Accreditation Statements

Jointly Accreditation Logo 
 
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

NCCN designates this live activity for a maximum of 5.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

NCCN designates this educational activity for a maximum of 5.5 contact hours.

Pharmacists

NCCN designates this knowledge-based continuing education activity for 5.5 contact hours (0.55 CEUs) of continuing education credit. UAN: JA4008196-0000-20-001-L01-P

Physician Assistants

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 5.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.



American Board of Internal Medical Maintenance of Certification (MOC)


CME-MOC_badge1 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.5 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Aggregated participant data will be shared with the commercial supporters of this activity.


American Board of Pathology Maintenance of Certificate (MOC)

ABPath Logo 

This activity has been registered to offer credit in the American Board of Pathology's (ABPath) Maintenance of Certification program. Successful completion of this CME activity enables the participant to earn up to 5.5 Lifelong Learning (Part II) credits.

Aggregated participant data will be shared with the commercial supporters of this activity.

Requirements for Receiving CE Credit

Before or during the congress, please ensure that you have an NCCN account and will receive the correct type of credit.  

  1. Log in at http://www.nccn.org
    • If you do not have an NCCN account, click “Sign up here” to create one for free.
  2. Click “Profile” in the left side menu.
  3. Verify that your User Type matches the type of credit you will claim:
    • Physician/Surgeon/Oncologist = physician credits; ABIM MOC points, if applicable*
    • Pharmacist = pharmacist CEUs**
    • Nurse Practitioner = nurse contact hours; physician credits
    • Clinical Nurse Specialist = nurse contact hours
    • Nurse/Oncology Nurse = nurse contact hours
    • Case Manager (Nurse) = nurse contact hours
    • All other user types = certificate of participation
  4. Scroll down and click “Save” if you make any changes

Within 5 business days of this educational activity, you will receive an e-mail with instructions on how to complete the CE requirements online through NCCN’s Continuing Education Portal (http://education.nccn.org). Within 30 days of the activity, you must: 

Attend the activity
Complete the immediate post-test
Complete the evaluation

Claim your credits

You will be able to view/print your certificate online once all requirements have been met.

*Physicians claiming ABIM/ABPath MOC points: MOC points are reported to ABIM and ABPath once you have completed the post-test and evaluation and claimed your credits. Before completing these requirements, be sure your NCCN profile has been updated with your ABIM/ABPath learner ID and date of birth. Your credit cannot be reported without this information.

**Pharmacists: You must complete the post-test and evaluation within 30 days of the activity. Continuing pharmacy education credit is reported to the CPE Monitor once you have completed the post-test and evaluation and claimed your credits. Before completing these requirements, be sure your NCCN profile has been updated with your NAPB e-profile ID and date of birth. Your credit cannot be reported without this information.

If you have any questions, please e-mail education@nccn.org.

Disclosure of Relevant Financial Relationships

It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Outlook Outlook
iCal iCal
Google Google
Yahoo! Yahoo!
MSN MSN
Top